Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lisata Therapeutics (LSTA) Debt to Equity (2016 - 2017)

Lisata Therapeutics filings provide 8 years of Debt to Equity readings, the most recent being $0.01 for Q2 2017.

  • For the quarter ending Q2 2017, Debt to Equity fell 99.44% year-over-year to $0.01, compared with a TTM value of $0.01 through Jun 2017, down 99.44%, and an annual FY2016 reading of $1.03, up 406.64% over the prior year.
  • Debt to Equity hit $0.01 in Q2 2017 for Lisata Therapeutics, up from -$1.73 in the prior quarter.
  • The five-year high for Debt to Equity was $1.56 in Q2 2016, with the low at -$1.73 in Q1 2017.
  • Median Debt to Equity over the past 5 years was $0.11 (2013), compared with a mean of $0.2.
  • The sharpest move saw Debt to Equity surged 3845.76% in 2016, then plummeted 362.94% in 2017.
  • Year by year, Debt to Equity stood at $0.01 in 2013, then surged by 2916.19% to $0.26 in 2014, then fell by 20.94% to $0.2 in 2015, then skyrocketed by 406.64% to $1.03 in 2016, then tumbled by 99.15% to $0.01 in 2017.
  • According to Business Quant data, Debt to Equity over the past three periods came in at $0.01, -$1.73, and $1.03 for Q2 2017, Q1 2017, and Q4 2016 respectively.